Menopausal hormone replacement therapy and breast cancer: A meta‐analysis

Sillero-Arenas, Marı́a; Delgado-Rodriquez, M; Rodigues-Canteras, R; Bueno‐Cavanillas, Aurora; Gálvez-Vargas, Ramón

doi:10.1016/0020-7292(92)90949-j

Cited by 87 publications

(60 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…70,[83][84][85][86][87][88][89] However, current use of estrogen is associated with an increased breast cancer risk according to 3 meta-analyses (RRs, 1.21-1.40). [83][84][85] Risk increases with longer duration of use in all the metaanalyses that evaluated this relationship (RRs, 1.23-1.35).…”

Section: Breast Cancermentioning

confidence: 99%

Postmenopausal Hormone Replacement Therapy

Nelson¹,

Humphrey²,

Nygren³

et al. 2002

JAMA

923

504

View full text Add to dashboard Cite

PPROXIMATELY 38% OF POSTmenopausal women in the United States in 1995 used h o r m o n e r e p l a c e m e n t therapy (HRT), estrogen with or without progestin, to treat symptoms of menopause and prevent chronic conditions such as cardiovascular disease and osteoporosis. 1 Although treatment of symptoms of menopause, such as hot flashes and urogenital atrophy, among others, is a common indication for short-term use, potential preventive effects of HRT on long-term health outcomes have become an increasingly important consideration.In 1996, the second US Preventive Services Task Force (USPSTF) determined that there was insufficient evidence to recommend for or against HRT for all women but thought that individual decisions should be based on patient risk factors, an understanding of the probable benefits and harms, and personal preferences. 2 Many studies have been published since these recommendations were released, including the first report from the Women's Health Initiative (WHI), 3 a large randomized primary prevention trial, and the Heart and Estrogen/ progestin Replacement Study (HERS), 4 a secondary prevention trial reporting multiple outcomes. [4][5][6] This review was initiated to aid the current USPSTF in making new recommendations that will be Author Affiliations and Financial Disclosures are listed at the end of this article.

show abstract

Section: Breast Cancermentioning

confidence: 99%

Postmenopausal Hormone Replacement Therapy

Nelson¹,

Humphrey²,

Nygren³

et al. 2002

JAMA

923

504

View full text Add to dashboard Cite

show abstract

“…One recent meta-analysis revealed that the use of hormonal replacement therapy was associated with a small increased risk (Sillero-Arenas et al 1992). Another meta-analysis revealed essentially the same results; in this particular report the increased risk was noted in patients who used estrogen for at least 5 years (Steinberg et al 1991).…”

Section: Risk Factorsmentioning

confidence: 73%

Progress in breast cancer chemoprevention.

Arun

Hortobágyi²

2002

Endocrine-Related Cancer

View full text Add to dashboard Cite

Over the past years there have been significant advances in breast cancer treatment and early detection. For the first time, a decrease in cancer mortality has been observed. Recently, much progress has been made in the understanding of carcinogenesis partly due to available new technologies to detect early molecular changes in the tissue. The knowledge of breast cancer carcinogenesis has provided possible opportunities to prevent breast cancer. Currently, several clinical breast cancer prevention trials are ongoing. This paper reviews issues related to breast cancer chemoprevention including identification of high risk cohorts, endpoint biomarkers, current and new chemopreventive agents as well as models to evaluate these agents.

show abstract

“…However, some studies have suggested that the long-term use of oral contraceptives in young women before first birth may increase breast cancer risk (182,183). Two recent meta-analyses of the effect of estrogen replacement therapy demonstrate small but statistically significant increases in risk for users (184,185). However, Steinberg et al (184) noted no increase in risk until after at least 5 yr of estrogen use, after which a proportional increase in risk for each year of estrogen use was observed, while Sillero-Arenas et al (185) did not observe a significant association between duration of hormone replacement therapy and breast cancer risk.…”

Section: Risk Factors For Breast Cancermentioning

confidence: 91%

“…Two recent meta-analyses of the effect of estrogen replacement therapy demonstrate small but statistically significant increases in risk for users (184,185). However, Steinberg et al (184) noted no increase in risk until after at least 5 yr of estrogen use, after which a proportional increase in risk for each year of estrogen use was observed, while Sillero-Arenas et al (185) did not observe a significant association between duration of hormone replacement therapy and breast cancer risk. In summary, although hormonal risk factors are clearly implicated in the pathogenesis of breast cancer, most of them are associated with a RR of 3 or less of breast cancer development (Table 4), and the presence of a single hormonal risk factor is insufficient to classify a woman as high risk.…”

Section: Risk Factors For Breast Cancermentioning

confidence: 91%